NuGen M.D. Announces a $333,000, 5-Year Distribution Agreement with Intermediq for its InsuJet(TM) Needle-Free Injection Device

3 years ago

TORONTO, ON / ACCESSWIRE / January 18, 2022 / NuGen Medical Devices Inc. (TSXV:NGMD) ("NuGen M.D." or the "Company") is…

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

3 years ago

WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® technology has received…

Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent

3 years ago

Company identifies unique two-part extraction and transdermal delivery processVANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp.…

Research Finds All-Cause Hospitalizations are Nearly Three Times More Likely During a Diabetic Foot Ulcer Episode

3 years ago

All-cause mortality is 50% more likely during this common diabetes complicationSOMERVILLE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Podimetrics, a…

Truepill Launches COVID-19 Test Coverage Platform to Help Insurance Companies and Group Health Plans Meet Direct Coverage Requirements

3 years ago

First-of-its-kind platform provides a turnkey solution to reduce costs and increase access to testingSAN MATEO, Calif., Jan. 18, 2022 (GLOBE…

Taconic Biosciences Adds New Humanized Immune System (HIS) Model to Its Portfolio For Immuno-Oncology Research

3 years ago

New huNOG-EXL EA Model Extends Study Windows SignificantlyRENSSELAER, N.Y., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader…

Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler)

3 years ago

Brazil Phase 2 Pulmonary Long-Hauler clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal…

Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones

3 years ago

Strong enrollment within multi-cohort TRIDENT-1 Phase 2 registration enabling study of repotrectinib; completion of targeted 60 patients within EXP-4 ROS1+…

Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562

3 years ago

PRAX-562 demonstrated robust preclinical antiseizure activity and exhibited an improved preclinical tolerability profile compared to standard-of-care Praxis expects to initiate…

Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis

3 years ago

SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life…